NDLI: Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Please wait, while we are loading the content...

A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds.

Pretreatment with flurbiprofen axetil, flurbiprofen axetil preceded by venous occlusion, and a mixture of flurbiprofen axetil and propofol in reducing pain on injection of propofol in adult Japanese surgical patients: a prospective, randomized, double-blind, placebo-controlled study.

Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.

A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.

Pharmacokinetics and bioequivalence evaluation of two formulations of 10-mg amlodipine besylate: an open-label, single-dose, randomized, two-way crossover study in healthy Chinese male volunteers.

Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.

Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: a randomized, open-label, crossover study in healthy Korean male subjects.

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.

An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.

Standing on the shoulders of Mark H. Beers: more than a giant in geriatric medicine.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.

Gastroprotective drugs in Australia: utilization patterns between 1997 and 2006 in relation to NSAID prescribing.

Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.

The financial implications for Medicare of greater use of peritoneal dialysis.

Modified visual analog scale symptom-intensity and overall-bother measures for the assessment of symptoms in studies of pharmacologic stress agents.

Interpreting treatment-effect estimates with heterogeneity and choice: simulation model results.

Year: 2009 Volume: 31 Issue: 3

Year: 2009 Volume: 31 Issue: 2

Year: 2009 Volume: 31 Issue: Supplementary 2

Year: 2009 Volume: 31 Issue: 1

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Ollendorf, Daniel A. Klingman, David Hazard, Elisabeth Ray, Saurabh
Description	Country affiliation: United States Author Affiliation: Ollendorf DA ( IMS Health, Inc., Norwalk, Connecticut, USA. dollendorf@icer-review.org)
Abstract	BACKGROUND: Tumor necrosis factor (TNF) antagonists are commonly used to treat rheumatoid arthritis (RA). Differences in the dosage and mode of administration of these agents may result in differential rates of dosage adjustment and costs of care. OBJECTIVE: This study compared dosing patterns and annual costs associated with the use of the subcutaneous TNF antagonists adalimumab and etanercept, and the intravenous TNF antagonist infliximab. METHODS: A large managed care database (PharMetrics) was used to identify patients with RA who newly initiated TNF-antagonist therapy with adalimumab, etanercept, or infliximab on or after January 1, 2003, and had at least 6 months of continuous health plan enrollment before initiation of therapy and 12 months of continuous enrollment after initiation. The patients were followed over 12 months of enrollment. Annual pharmacy, inpatient, and outpatient costs were estimated based on plan reimbursements and were compared between cohorts. The average daily dosage (ADD) between prescription refills was used to compare the percentages of patients with greater-than-expected dosing (GTED), defined as 2 consecutive increases in ADD relative to the patient's established maintenance dosage. RESULTS: A total of 2382 patients (568 adalimumab, 1181 etanercept, 633 infliximab) were included in the analysis. Significantly more patients had GTED with infliximab compared with adalimumab and etanercept (32.1%, 8.5%, and 4.7%, respectively; both comparisons, P < 0.05). For patients with a dosage increase, the mean time to the first GTED was significantly shorter for infliximab compared with adalimu-mab and etanercept (154.5, 173.3, and 167.9 days; both, P < 0.05). The mean annual costs of anti-TNF therapy, adjusted for baseline differences, were significantly greater for infliximab compared with adalimumab and etanercept (\$15,617, \$12,200, and \$12,146; both, P < 0.05). There were also significant differences between infliximab relative to adalimumab and etanercept in total RA-related medication costs (\$16,280, \$12,989, and \$12,794; P < 0.05) and total pharmacy costs (\$17,854, \$14,805, and \$14,398; P < 0.05). CONCLUSION: Patients initiating TNF-antagonist treatment for RA with infliximab incurred annual medication costs that were nearly 30% greater than costs in those initiating therapy with adalimumab or etanercept, in part because of the significantly greater rate of GTED in infliximab recipients.
File Format	HTM / HTML
ISSN	01492918
Issue Number	4
Volume Number	31
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2009-04-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Antibodies, Monoclonal Therapeutic Use Antirheumatic Agents Arthritis, Rheumatoid Drug Therapy Adalimumab Adult Administration & Dosage Economics Antibodies, Monoclonal, Humanized Cohort Studies Databases, Factual Dose-response Relationship, Drug Drug Costs Etanercept Female Follow-up Studies Humans Immunoglobulin G Infliximab Injections, Intravenous Injections, Subcutaneous Longitudinal Studies Male Managed Care Programs Middle Aged Pharmaceutical Services Receptors, Tumor Necrosis Factor Tumor Necrosis Factor-alpha Antagonists & Inhibitors Comparative Study Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: Comment on the article.

Economic impact of rheumatoid arthritis (RA) biotherapies in France.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Estimated medication costs of primary TNF antagonist failure in patients with rheumatoid arthritis.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.

Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification.

Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Similar Documents

Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: Comment on the article.

Economic impact of rheumatoid arthritis (RA) biotherapies in France.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Estimated medication costs of primary TNF antagonist failure in patients with rheumatoid arthritis.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.

Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modification.

Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.